Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Persistence Study of GSK Biologicals' Tdap Vaccine (776423), 1, 3, 5 and 9 Years Following Administration as a Single Dose in NCT00346073 Study and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

NCT00489970 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00489970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00489970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Persistence Study of GSK Biologicals' Tdap Vaccine (776423), 1, 3, 5 and 9 Years Following Administration as a Single Dose in NCT00346073 Study and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
June 1, 2007
Completion date
March 1, 2016
Enrollment
1,954 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, tetanus